News Archive

News Archive

Article Name

Link

STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica

Read article

Ladival wins 'Best Beach Sun Protection 2017'

Read article

T&R signs licensing agreement with Futura Medical

Read article

T&R acquires Natures Aid Ltd

Read article

T&R licenses K-Y Jelly

Read article

T&R acquires Flexitol

Read article

STADA AG completes acquisition of T&R

Read article

Celebrating 90 years of a British institution

Read article

Derma new business shows steady growth

Read article

Thornton & Ross Ltd acquires the Allens brand

Read article



Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

Bad Vilbel, September 3, 2018 – Peter Goldschmidt (53) succeeded Claudio Albrecht as the Chief Executive Officer of STADA Arzneimittel AG (‘STADA’ or ‘the Group’) with effect from September 1, 2018. Goldschmidt is an experienced generics manager and OTC expert who was most recently President of SANDOZ US, the global generics division of Novartis, and Head of North America. Goldschmidt will be focused on continuing STADA’s growth strategy that Albrecht successfully reinvigorated and advanced in 2017

“Peter Goldschmidt is the right man that STADA needs in the driving seat going forward,” said Chairman of the Supervisory Board Günter von Au. “With his three decades of experience, I am confident he will ensure that STADA successfully retains its strong competitive position,” added von Au. He describes Goldschmidt as a “strong team player who has a long-term focus on building the portfolio and an excellent network in the pharmaceutical world

Originally from Höxter in East Westphalia, Goldschmidt came to STADA from the Novartis Group, where he held various senior management positions in Europe, Asia, and the US over the past 28 years. In his past position as the President of Sandoz USA and the Head of North America, he rapidly expanded the company’s generics and biosimilar business over the past five years to generate revenue in excess of USD 3 billion

Previously, Peter Goldschmidt was also the Global Executive Member for Central and Eastern Europe for Sandoz, where he led Sandoz to a market leading position in generics and strongly grew its OTC business. He also held various senior leadership positions at Novartis Pharma in Asia and Europe during his career. “Naturally I have known STADA as a key player in the industry for many years, and I see enormous potential for the Group. Together with all employees we will strive to fully capitalise on the opportunities for growth,” announced the new CEO

Goldschmidt intends to use the next 100 days to intensively get to know the Group, its partners, and its customers, and will then discuss his strategic priorities with his team. “I look forward to working with the highly experienced team at STADA to continue the Group’s long-term growth,” said the new CEO. Goldschmidt also described the excitement of the work ahead as another reason for joining STADA. “I am in complete alignment with our majority owners, Cinven and Bain Capital, on their strategy for building a company with long-term growth potential. Using the financial resources at their disposal, our focus remains on continuing to market a competitive portfolio and working closely with our global network of strategic development and production partners

Goldschmidt thanked Claudio Albrecht for the professional and amicable handover. Under the German government’s “cooling-off” regulation of 2009, Albrecht will not be taking a seat on the STADA Group’s Supervisory Board. “I am proud that, together with the high quality team at STADA and the Supervisory Board, we have successfully managed to turn STADA around, both in terms of business development and corporate governance and we will continue to focus on maintaining exemplary corporate governance standards and conduct. Naturally, I will continue to support the STADA Group and I wish Peter Goldschmidt and his team all the best,” said the outgoing CEO

“Claudio Albrecht and his team played a fundamental role in setting out the Group’s strategy and initiating key process changes. We now have a great foundation that we can build on,” concluded Goldschmidt

Günter von Au added: “On behalf of the Board of Stada and our major shareholders, I would like to thank Claudio for his exceptional contribution to STADA. He has worked tirelessly to redefine STADA’s growth strategy and to steer the Group towards its new path for success. We are very grateful for his dedication

Peter Goldshmidt and Claudio Albrecht
STADA's new CEO Peter Goldschmidt (left) thanked his predecessor Claudio Albrecht for the professional and friendly handover and got an initial overview of some of the company's best-selling products.

Thornton & Ross launches alternative, cost-effective treatment for osteoporosis in UK

Huddersfield, September 10, 2019 – West Yorkshire-based pharmaceutical company Thornton & Ross (T&R) is launching an alternative, cost-effective treatment for osteoporosis.

Movymia® teriparatide was launched at the end of August, when the patent for Forsteo® teriparatide – the only approved osteoanabolic therapy for osteoporosis in the UK – expired.

Movymia® will offer the NHS a teriparatide which has been evaluated by the European Medicines Agency and deemed to be similar to Forsteo® teriparatide but at a more a cost-effective list price .

The product is injected using a refillable, multi-dose injection device called a Movymia® Pen, which is used for the entire treatment period – allowing the NHS to remain environmentally friendly.

Movymia® is the first of a significant pipeline of biosimilar products due to be launched by T&R and underlines the company’s commitment to providing the NHS with cost-effective treatment options. It complements T&R’s extensive bone health portfolio, which includes Fultium® D3, Accrete® D3 and Binosto®.

Roger Scarlett-Smith, T&R’s Executive Vice President UK, said: “The launch of Movymia® is an important expansion of the STADA group’s biosimilar portfolio in the UK, and is a sign of our ongoing commitment to improving treatment options for people living with osteoporosis.”

Alison Doyle, Head of Clinical and Operations at the Royal Osteoporosis Society, added: “We are delighted that teriparatide – an effective anabolic treatment for osteoporosis – is now available as a biosimilar following the expiration of the Forsteo® patent.

“This once expensive medication was rationed by NICE guidance until last year, when NHS England announced the treatment would be available to men as well as women. While we are aware that some men still struggle to get access to Teriparatide, the availability of biosimilars should drive down the cost of treatment and make it available to more people with osteoporosis.

“Improved choice in the current offering of clinically effective treatments for osteoporosis is welcome news for healthcare professionals and people with osteoporosis alike.

A biosimilar is a pharmaceutical product manufactured by using biotechnology with a protein as active ingredient developed with the aim of being comparable to an existing biological pharmaceutical product (the “reference pharmaceutical product”). There are no significant differences in quality, safety and effectiveness between biosimilars and reference pharmaceutical products.

News

Thornton & Ross launches alternative, cost-effective treatment for osteoporosis in UK

West Yorkshire-based pharmaceutical company Thornton & Ross (T&R) is launching an alternative, cost-effective treatment for osteoporosis.

Click for more info

Thornton & Ross to acquire established GSK Consumer Health brands

Thornton & Ross has expanded its Consumer Health business with a contract to acquire four UK skin care brands, as well as a paediatric cough remedy, from GlaxoSmithKline. Completion of the deal is expected to occur by August 2019.

Click for more info

Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

STADA Arzneimittel AG Appoints Peter Goldschmidt as CEO to suceed Claudio Albrecht.

Click for more info

STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica

STADA Arzneimittel AG is further strengthening its position in branded over-the-counter healthcare products.

Click for more info

Ladival wins 'Best Beach Sun Protection 2017'

Thornton & Ross is pleased to announce that Ladival Sun Protection Lotion SPF30 has won the 'Best Beach Sun Protection' in this year's Best Beauty by Stylist Awards 2017.

Click for more info

Thornton & Ross Ltd signs licensing agreement with Futura Medical

Thornton & Ross is pleased to announce it has entered in to a long-term licensing agreement with Futura Medical.

Click for more info

Thornton & Ross Ltd acquires Natures Aid Ltd

Thornton & Ross Ltd is pleased to announce that it has acquired the Natures Aid business, a leading UK manufacturer and distributor of premium quality branded vitamins, minerals, food supplements and herbal products.

Click for more info

Thornton & Ross Ltd licenses "K-Y Jelly" brand from Reckitt Benckiser

Thornton & Ross Ltd is pleased to announce that it has entered into a licensing agreement with Reckitt Benckiser (RB) for the K-Y Jelly brand in the UK.

Click for more info

>> News Archive